The reach of the mifepristone ruling
Sen. Tammy Baldwin (Photo by Bill Clark/CQ Roll Call via AP Images) ‘Extremist’ Texas judge’s ruling could have impact far beyond reproductive health LISA KEEN | Keen News Servicelisakeen@mac.com The escalating clash over the availability of a certain FDA-approved medication to terminate an early-stage pregnancy has significant implications for many LGBTQ people.
Over the years, various entities have tried to block the use of hormones for gender transition and medications for HIV prevention.
Now, the court battles raging over the abortion drug RU-486 (also known as mifepristone) could determine whether any federal judge has the power to pull any controversial medication off the market.
Lambda Legal Chief Legal Officer Jenny Pizer So there was guarded appreciation on Friday, April 21, when the U.S. Supreme Court announced that it would grant a stay against a lower court decision in Texas that sought to pull RU-486 off the market. (Two justices — Clarence Thomas and Samuel Alito — dissented from the stay.) “While today’s ruling to keep this safe, effective drug available for the time being is a sense of relief,” said U.S.
